312 related articles for article (PubMed ID: 36395497)
1. Chimeric Antigen Receptor Structure and Manufacturing of Clinical Grade CAR Engineered Cells using Different Bioreactors.
Syed F; El Fakih R; Alahmari AD; Osman Ali AS; Aljurf M
Hematol Oncol Stem Cell Ther; 2022 Nov; 15(3):137-152. PubMed ID: 36395497
[TBL] [Abstract][Full Text] [Related]
2. Platforms for Clinical-Grade CAR-T Cell Expansion.
Mizukami A; Swiech K
Methods Mol Biol; 2020; 2086():139-150. PubMed ID: 31707673
[TBL] [Abstract][Full Text] [Related]
3. Engineering strategies to overcome the current roadblocks in CAR T cell therapy.
Rafiq S; Hackett CS; Brentjens RJ
Nat Rev Clin Oncol; 2020 Mar; 17(3):147-167. PubMed ID: 31848460
[TBL] [Abstract][Full Text] [Related]
4. Strategies for manufacturing cell therapy products aligned with patient needs.
Guha P; Katz SC
Methods Cell Biol; 2022; 167():203-226. PubMed ID: 35152997
[TBL] [Abstract][Full Text] [Related]
5. GMP-Grade Manufacturing of T Cells Engineered to Express a Defined γδTCR.
Straetemans T; Kierkels GJJ; Doorn R; Jansen K; Heijhuurs S; Dos Santos JM; van Muyden ADD; Vie H; Clemenceau B; Raymakers R; de Witte M; Sebestyén Z; Kuball J
Front Immunol; 2018; 9():1062. PubMed ID: 29899740
[TBL] [Abstract][Full Text] [Related]
6. A quality-by-design approach to improve process understanding and optimise the production and quality of CAR-T cells in automated stirred-tank bioreactors.
Hood T; Slingsby F; Sandner V; Geis W; Schmidberger T; Bevan N; Vicard Q; Hengst J; Springuel P; Dianat N; Rafiq QA
Front Immunol; 2024; 15():1335932. PubMed ID: 38655265
[No Abstract] [Full Text] [Related]
7. Recent advances in the production, reprogramming, and application of CAR-T cells for treating hematological malignancies.
Vandghanooni S; Eskandani M; Sanaat Z; Omidi Y
Life Sci; 2022 Nov; 309():121016. PubMed ID: 36179813
[TBL] [Abstract][Full Text] [Related]
8. Biomaterials for chimeric antigen receptor T cell engineering.
Niu H; Zhao P; Sun W
Acta Biomater; 2023 Aug; 166():1-13. PubMed ID: 37137403
[TBL] [Abstract][Full Text] [Related]
9. Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From an Academic Phase I Clinical Trial.
Castella M; Caballero-Baños M; Ortiz-Maldonado V; González-Navarro EA; Suñé G; Antoñana-Vidósola A; Boronat A; Marzal B; Millán L; Martín-Antonio B; Cid J; Lozano M; García E; Tabera J; Trias E; Perpiña U; Canals JM; Baumann T; Benítez-Ribas D; Campo E; Yagüe J; Urbano-Ispizua Á; Rives S; Delgado J; Juan M
Front Immunol; 2020; 11():482. PubMed ID: 32528460
[TBL] [Abstract][Full Text] [Related]
10. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
11. Better by design: What to expect from novel CAR-engineered cell therapies?
Luginbuehl V; Abraham E; Kovar K; Flaaten R; Müller AMS
Biotechnol Adv; 2022 Sep; 58():107917. PubMed ID: 35149146
[TBL] [Abstract][Full Text] [Related]
12. Automated production of gene-modified chimeric antigen receptor T cells using the Cocoon Platform.
Trainor N; Purpura KA; Middleton K; Fargo K; Hails L; Vicentini-Hogan M; McRobie C; Daniels R; Densham P; Gardin P; Fouks M; Brayer H; Malka RG; Rodin A; Ogen T; Besser MJ; Smith T; Leonard D; Bryan A
Cytotherapy; 2023 Dec; 25(12):1349-1360. PubMed ID: 37690020
[TBL] [Abstract][Full Text] [Related]
13. Generation of CAR-T Cells for Cancer Immunotherapy.
Xu Q; Harto H; Berahovich R; Xu S; Zhou H; Golubovskaya V; Wu L
Methods Mol Biol; 2019; 1884():349-360. PubMed ID: 30465215
[TBL] [Abstract][Full Text] [Related]
14. Development and Validation of a Good Manufacturing Process for IL-4-Driven Expansion of Chimeric Cytokine Receptor-Expressing CAR T-Cells.
van Schalkwyk MCI; van der Stegen SJC; Bosshard-Carter L; Graves H; Papa S; Parente-Pereira AC; Farzaneh F; Fisher CD; Hope A; Adami A; Maher J
Cells; 2021 Jul; 10(7):. PubMed ID: 34359966
[TBL] [Abstract][Full Text] [Related]
15. Chimeric antigen receptor T-cells: Properties, production, and quality control.
Ramesh P; Hui HYL; Brownrigg LM; Fuller KA; Erber WN
Int J Lab Hematol; 2023 Aug; 45(4):425-435. PubMed ID: 37337970
[TBL] [Abstract][Full Text] [Related]
16. Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.
Gorchakov AA; Kulemzin SV; Kochneva GV; Taranin AV
Eur Urol; 2020 Mar; 77(3):299-308. PubMed ID: 31471138
[TBL] [Abstract][Full Text] [Related]
17. [CAR T cells as drugs for novel therapies (advanced therapy medicinal products)].
Köhl U; Abken H
Internist (Berl); 2021 Apr; 62(4):449-457. PubMed ID: 33590292
[TBL] [Abstract][Full Text] [Related]
18. Generation of Redirected Engineered Human Chimeric Antigen Receptor (CAR) T Cells.
Bunse M; Höpken UE
Methods Mol Biol; 2022; 2521():67-83. PubMed ID: 35732993
[TBL] [Abstract][Full Text] [Related]
19. T Cell Activation Machinery: Form and Function in Natural and Engineered Immune Receptors.
Chandler NJ; Call MJ; Call ME
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33050044
[TBL] [Abstract][Full Text] [Related]
20. The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy.
Liu D; Badeti S; Dotti G; Jiang JG; Wang H; Dermody J; Soteropoulos P; Streck D; Birge RB; Liu C
Cell Commun Signal; 2020 Aug; 18(1):134. PubMed ID: 32843053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
